@article{d33e8edfcce447aab8d10e945db86b24,
title = "Comparison of sotalol versus amiodarone in maintaining stability of sinus rhythm in patients with atrial fibrillation (Sotalol-Amiodarone Fibrillation Efficacy Trial [Safe-T])",
abstract = "The Sotalol-Amiodarone Fibrillation Efficacy Trial (SAFE-T) is a randomized, double-blind, multicenter, placebo-controlled trial in which the effects of sotalol and amiodarone in maintaining stability of sinus rhythm are being examined in patients with persistent atrial fibrillation at 20 Veterans Affairs medical centers. The time to the occurrence of atrial fibrillation or flutter in patients with atrial fibrillation converted to sinus rhythm is the primary outcome measure, with a number of parameters as secondary end points. SAFE-T had randomized 665 patients when enrollment terminated on October 31, 2001. Follow-up of patients continued until October 31, 2002, for a maximum period of 54 months and a minimum period of 12 months for all patients.",
author = "Singh, {Steven N.} and Singh, {Bramah N.} and Reda, {Domenic J.} and Fye, {Carol L.} and Ezekowitz, {Michael D.} and Fletcher, {Ross D.} and Sharma, {Satish C.} and Atwood, {J. Edwin} and Jacobson, {Alan K.} and Lewis, {H. Daniel} and Antman, {Eliott M.} and Falk, {Rodney H.} and Becky Lopez and Tang, {X. Charlene}",
note = "Funding Information: This study was supported by the Cooperative Studies Program of the Department of Veterans Affairs Office of Research and Development. The blinded drug preparations and their respective placebos were provided by Wyeth Pharmaceuticals (amiodarone), Philadelpha, Pennsylvania, and Berlex Pharmaceuticals (sotalol), Atlanta, Georgia. Both companies also provided additional funds in support of the study in general. ",
year = "2003",
month = aug,
day = "15",
doi = "10.1016/S0002-9149(03)00671-4",
language = "English",
volume = "92",
pages = "468--472",
journal = "The American Journal of Cardiology",
issn = "0002-9149",
number = "4",
}